Skip to main content

Advertisement

Table 2 Proportion of patients with relapses or confirmed disability progression, Year 2 (PRISMS-2) and 4 (PRISMS-4)

From: Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study

  Placebo/delayed treatment (n = 187) IFN β-1a 22 μg SC tiw (n = 189) IFN β-1a 44 μg SC tiw (n = 184)
Relapse by Year 2 (%) 84.5 73.0 67.9
Relapse by Year 4 (%) 90.4 82.0 78.8
Confirmed EDSS progression by Year 2 (%) 39.0 31.2 27.7
Confirmed EDSS progression by Year 4 (%) 48.1 45.0 39.7
  1. EDSS progression was defined as an increase of ≥0.5 points if baseline EDSS was ≥6 or increase of ≥1 point if baseline EDSS was < 6, confirmed 3 months later
  2. EDSS Expanded Disability Status Scale, IFN β-1a interferon beta-1a, SC subcutaneously, tiw three times weekly